First AD

Second AD

Unmet Needs in Current IgAN Treatment

What do you believe are the most significant unmet needs in the current treatment landscape for IgA nephropathy?

Videos

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Advancing IgAN Care: Exploring the Next Wave of Treatments

Biomarkers and clinical indicators play a crucial role in predicting disease outcomes, offering insights into disease progression, treatment response, and patient prognosis. These indicators can be genetic, molecular, or cellular, and are often identified through advanced diagnostic techniques. For instance, specific gene mutations or protein expressions can indicate the likelihood of disease recurrence or metastasis. Additionally, clinical indicators such as tumor size, stage, and patient health status are integral in assessing outcomes. Personalized medicine leverages these biomarkers to tailor treatment plans, enhancing therapeutic efficacy and patient survival rates.

Panelists discuss how the current treatment landscape for IgA nephropathy presents significant unmet needs, particularly in addressing the underlying causes of the disease and improving patient outcomes.

Overview of IgAN and Its Common Symptoms

IgAN Progression

IgAN vs Other Glomerular Diseases

Biomarkers for IgAN

Genetic Screening for IgAN

Impact of IgAN on Quality of Life

Misdiagnosis and Barriers to Early Detection of IgAN

Differential Diagnoses of IgAN

Significance of Proteinuria for Potential IgAN

Proteinuria Variability and IgAN Diagnosis

Biomarkers and Improving IgAN Diagnostic Accuracy

Primary Treatment Goals for Patients With IgAN

Proteinuria Reduction in Long-Term Kidney Damage Prevention

Symptoms Management and Targeting the Root Cause of IgAN

Prospective Improvements of Existing IgAN Therapies